Rankings
▼
Calendar
IRWD Q1 2023 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
IRWD
Ironwood Pharmaceuticals, Inc.
$629M
Q1 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$104M
+6.7% YoY
Gross Profit
$104M
99.7% margin
Operating Income
$60M
57.8% margin
Net Income
$46M
43.9% margin
EPS (Diluted)
$0.25
QoQ Revenue Growth
-2.9%
Cash Flow
Operating Cash Flow
$80M
Free Cash Flow
$80M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$448M
Stockholders' Equity
$707M
Cash & Equivalents
$742M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$104M
$98M
+6.7%
Gross Profit
$104M
$87M
+19.7%
Operating Income
$60M
$58M
+3.9%
Net Income
$46M
$39M
+17.8%
Revenue Segments
Collaborative arrangements revenue
$104M
99%
Collaborative arrangement, other agreements
$580,000
1%
Collaborative arrangement, collaboration and license agreements
$91,000
0%
Geographic Segments
North America
$700,000
50%
Canada and Mexico
$700,000
50%
← FY 2023
All Quarters
Q2 2023 →